Karkinos is in the business of providing technology-driven, innovative solutions for the early detection, diagnosis, and management of cancer.
The investment will empower RDHL to develop a virtual diagnostic and care platform, expanding access to healthcare for underserved communities
The segment has immense growth potential driven by the country's increasing healthcare needs, technological innovations, government support, and emerging market opportunities
The report also revealed that 87% of physicians agreed that FEE recommendations would help to improve the speed of recovery
Aims to become India’s leading cancer testing company
The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Xalatan
The first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma
In the near term, the company targets a 42% reduction in absolute Scope 1 and 2 emissions and Scope 3 emissions by FY2030
EBITDA for the quarter is Rs. 21.6 crore as against Rs. 18.1 crore in Q2 FY24
Subscribe To Our Newsletter & Stay Updated
